TIAA CREF Investment Management LLC Sells 456,405 Shares of Eli Lilly and Co (LLY)
TIAA CREF Investment Management LLC cut its holdings in Eli Lilly and Co (NYSE:LLY) by 10.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,871,066 shares of the company’s stock after selling 456,405 shares during the period. TIAA CREF Investment Management LLC’s holdings in Eli Lilly and were worth $326,950,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Gradient Investments LLC acquired a new position in Eli Lilly and in the 4th quarter valued at about $103,000. Avestar Capital LLC acquired a new position in Eli Lilly and in the 4th quarter valued at about $100,000. MPS Loria Financial Planners LLC acquired a new position in Eli Lilly and in the 2nd quarter valued at about $128,000. San Francisco Sentry Investment Group CA acquired a new position in Eli Lilly and in the 2nd quarter valued at about $129,000. Finally, Willingdon Wealth Management acquired a new position in Eli Lilly and in the 3rd quarter valued at about $138,000. Institutional investors and hedge funds own 77.58% of the company’s stock.
Several research analysts recently weighed in on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 5th. Credit Suisse Group reaffirmed a “hold” rating and set a $80.00 price objective on shares of Eli Lilly and in a research note on Friday, February 2nd. TheStreet downgraded shares of Eli Lilly and from a “b” rating to a “c” rating in a research note on Monday, March 5th. Argus raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and upped their price objective for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Finally, Jefferies Group set a $93.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a research note on Monday, February 26th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $93.47.
Shares of Eli Lilly and Co (NYSE LLY) opened at $79.15 on Wednesday. The stock has a market cap of $86,596.06, a P/E ratio of 18.47, a P/E/G ratio of 1.47 and a beta of 0.28. Eli Lilly and Co has a 1 year low of $73.69 and a 1 year high of $89.09. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The company’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.95 EPS. analysts expect that Eli Lilly and Co will post 4.87 earnings per share for the current year.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.